Iovance Biotherapeutics Shares Are Trading Higher After the Company Announced It Would Acquire the Rights of Treatment Proleukin for £166.7M.
Iovance Biotherapeutics Shares Are Trading Higher After the Company Announced It Would Acquire the Rights of Treatment Proleukin for £166.7M.
在該公司宣布將以 166.7 萬英鎊的價格獲得治療普洛伊金的權利之後，IOvance 生物治療藥物股票的交易價格走高。
Iovance Biotherapeutics shares are trading higher after the company announced it would acquire the rights of treatment Proleukin for £166.7M.
在該公司宣布將以 166.7 萬英鎊的價格獲得普洛萊金的治療權之後，IOvance 生物治療學股票的交易價格走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。